This Issue At A Glance

      In a systematic review and meta-analysis of published studies, Wan et al ( p. 2197) assessed the efficacy and safety of topical cyclosporine versus placebo for the treatment of allergic conjunctivitis. They found that topical cyclosporine is indeed safe and effective. In addition, they suggest that it may have a role in weaning corticosteroid-dependent allergic conjunctivitis patients from their steroid eye drops. For this meta-analysis, the researchers evaluated 7 randomized controlled trials (306 eyes of 153 patients) and assessed scores of composite signs and symptoms, reduction in steroid eye drop use, and safety outcomes. At 2 weeks or longer of follow-up, topical cyclosporine produced a statistically significant improvement in signs and symptoms, and its safety profile was comparable to that of placebo. Evidence suggesting that topical cyclosporine could be used in steroid-dependent patients was limited, the researchers acknowledged, but they said that it was suggestive of a positive effect.